English Funding Nod For Lilly’s Diabetes GLP-1 Mounjaro, Roche’s Cancer MAb Columvi

 
• By Eliza Slawther

Eli Lilly’s new type 2 diabetes injectable treatment Mounjaro is the latest GLP-1 to secure reimbursement in England following a positive opinion from HTA body NICE. Roche’s lymphoma drug Columvi and a new indication for UCB’s Bimzelx were also backed in recent draft guidance.

Close up of diverse young people show thumbs up recommending good quality service, multiethnic clients or customers
• Source: Shutterstock/fizkes

More from Market Access

More from Pink Sheet